Why Is PULSE BIOSCIENCES IN (PLSE) Stock Up Today?

Pulse Biosciences (PLSE) shares surged 12.41% to $42.98 in early trading on Tuesday driven by positive developments in its clinical trials and insider buying activity. The stock opened with a slight gap down but quickly reversed higher, reaching a session high of $42.99. The stock’s performance reflects optimism around the company’s progress in its NANOPULSE-AF study and recent insider purchases.

What Happened

Pulse Biosciences announced during its Q2 2026 earnings call on August 6 that its 164-patient NANOPULSE-AF study is on track to complete enrollment by early October. This update, shared by CEO Paul LaViolette, highlights the company’s ability to accelerate clinical timelines. The study, which began in April 2026, has already surpassed its enrollment midpoint, according to a recent update. These developments were disclosed in a Form 8-K filed with the SEC, which also included the company’s second-quarter financial results.

The company reported a loss of $0.36 per share for the quarter, in line with expectations but below the revenue estimate. Despite the unprofitable performance, the stock rose on the back of strong insider buying. CEO Paul LaViolette and board member Robert Duggan purchased shares through an ATM program on May 11, with total purchases amounting to $13.3 million. This activity suggests continued confidence in the company’s long-term prospects.

What The Data Shows

PLSE opened at $37.92 and traded as low as $37.40 before rising to a high of $42.99. The stock closed the session at $42.98, up from the prior close of $38.24. Trading volume reached 0.1 million shares, which is 0.4 times the 3-month daily average. The stock’s beta of 1.58 indicates it is more volatile than the broader market. PLSE currently trades within its 52-week range of $12.56 to $39.12, and its market cap stands at $2.6 billion. The company remains unprofitable with a trailing twelve-month EPS of -1.10.

What To Watch

The company is scheduled to report further updates on its clinical and financial progress in the coming quarters. Investors should monitor the enrollment timeline for the NANOPULSE-AF study and the company’s cash runway as key indicators of future momentum.